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S U M M A R Y
Objectives: Since measles presents mostly in children, a non-invasive sample collection technique such
as oral ﬂuid samplingwould be very useful in the early detection ofmeasles RNA and antibodies. The aim
of this study was to validate the detection of anti-measles IgM andmeasles virus RNA in oral ﬂuid and to
make a comparison with the gold standard methods of ELISA using serum (Enzygnost1 anti-Measles
IgM) and in-house nested reverse transcriptase polymerase chain reaction (RT-PCR) using nasopharyn-
geal secretions.
Methods: Three samples each from 73 measles-positive and 44 measles-negative subjects (serum, oral
ﬂuid, and nasopharyngeal secretions) were analyzed.
Results: The anti-measles IgM ELISA (MicroImmune) on oral ﬂuid was validated against the IgM ELISA
(Siemens) for serum and this resulted in a sensitivity of 92% and speciﬁcity of 100%. A molecular nested
RT-PCR using oral ﬂuid was validated against the standard assay on nasopharyngeal secretions and gave
a sensitivity of 100% and speciﬁcity of 100%.
Conclusions: The results conﬁrm that both serological and molecular oral ﬂuid assays are suitable for
routine use. The use of oral ﬂuid samples for the detection of measles virus may encourage patients,
general practitioners, and pediatricians to participate in the Belgian measles surveillance system and
other epidemiological studies in the framework of the World Health Organization elimination program.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Measles is a highly contagious viral disease characterized by
high fever, coryza, cough, and conjunctivitis, followed by the
appearance of a maculopapular rash. Measles virus (MV) is a
negative single-stranded RNA virus, belonging to the genus
Morbillivirus, of the family Paramyxoviridae.1
Despite the development of an efﬁcient combined vaccine
(measles–mumps–rubella), measles remains a major cause of
mortality in developing countries and a cause of continuous
outbreaks in industrialized countries.
Measles is transmittedorally (coughing, sneezing,andsaliva) and
has an incubation period of 10–12 days.2 Themeasles immunoglob-
ulin M (IgM) antibodies appear in the blood within 1 week of the
onset of the rash. The virus itself is detectable during the ﬁrst 7 days
after the appearance of symptoms, in the respiratory epithelium of
the nasopharynx and the regional lymph nodes.3 When oral ﬂuid is
sampled at an early stage (day 0–4) after the onset of the rash, more
than 80% of patients are positive for the measles virus and
approximately 80% are positive for measles IgM antibodies.3 The* Corresponding author. Tel.: +32 2 642 5690; fax: +32 2 642 5692.
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day 3 and day 7 after the appearance of the rash, respectively.2,3
Measles RNA is detectable from the onset of symptoms (i.e., high
fever) and declines from day 7 after the rash.3
In line with all the other countries in the World Health
Organization (WHO) European Region, Belgium is involved in the
WHOprogram for the elimination ofmeasles in Europe by 2010.4 To
achieve this goal, improved measles surveillance in Belgium is
necessary. More than 80% of themeasles cases should be laboratory
conﬁrmed, and vaccination coverage of >95% should be achieved.
However, in the case of a clinical measles diagnosis, general
practitioners (GPs) can be reluctant to take part in the surveillance
system, since sample collection (serum and/or nasopharyngeal
secretions) for laboratory conﬁrmation often requires invasive and
painful sampling in children.
Currently, in many countries, measles is still conﬁrmed by
serological and/or molecular assays on serum and nasopharyn-
geal secretions, respectively. In Europe, oral ﬂuid sampling and
assays have been increasingly introduced as a good alternative,
and one of the main WHO recommendations for the European
elimination program for measles is that these techniques should
be used.3–5
Saliva is a mixture of salivary gland secretions and gingival
crevicular ﬂuid (GCF). The composition of saliva includes water,ses. Published by Elsevier Ltd. All rights reserved.
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GCF contains plasma-derived immunoglobulins IgG and IgM and is
secreted via the crevicular epithelium, an area of higher
permeability than other regions in the oral cavity.7–9 The levels
of IgG and IgM in GCF are approximately 1/800 and 1/400 of those
found in serum, respectively.10
The detection of IgG and IgM antibodies and viral nucleic acids
(MV RNA) in oral ﬂuid enables the laboratory diagnosis of a variety
of viral infections. These antibodies transude from capillary beds in
the gingival crevice between the teeth and gums into the GCF
component of oral ﬂuid.8 They can be collected using an Oracol
collection device (Malvern Medical Development, UK).11 This
device, which was speciﬁcally developed for the collection of oral
ﬂuid rich in GCF, can yield samples that perform like serum in
antibody assays.8 It has previously been reported that the Oracol
collection device yields the highest quality of oral ﬂuid.12
The introduction of oral ﬂuid as an alternative medium to
serum for the detection of IgM and MV RNA would provide a
number of opportunities.11 Compared to traditional venipuncture,
the collection of oral ﬂuid is less invasive, less painful, less
expensive (i.e., no trained personnel required), and safer (preven-
tion of needle stick injuries).10 Since measles presents mostly in
children, a non-invasive sample collection method would be very
useful for the early detection of MV RNA and antibodies during
measles outbreaks. In addition, it could become a useful tool in the
control of outbreaks.
The aim of this study was to validate the detection of anti-
measles IgM and MV RNA in oral ﬂuid and to make a comparison
with the assays that are considered to be the gold standard: ELISA
on serum (Enzygnost1 anti-Measles IgM) and in-house nested
reverse transcriptase polymerase chain reaction (RT-PCR) on
nasopharyngeal secretions.
2. Materials and methods
2.1. Study population and sample collection
The study population consisted of 65 males and 52 females
(N = 117) with an age range of 3 months to 58 years from whom
three samples each were collected. The number of samples was
calculated to reach signiﬁcance for the validation of both assays.13
Most samples were collected in the Democratic Republic of
Congo by the National Measles Laboratory (Kinshasa) and came
from children living in a ghetto of the Congolese Police, situated in
the region of the city of Kinshasa. The positive samples came from
childrenwith clinicalmeasles symptoms, such as high fever, Koplik
spots, and rash andwere from the samemeasles outbreak. Healthy
children with no rash-illness, no fever or other disease symptoms
donated the control samples. All sampleswere collectedwithin the
same time period.
Some control samples were obtained from volunteers at the
Scientiﬁc Institute of Public Health (IPH), Brussels, Belgium. The
volunteerswere healthy adults, with no rash-illness and no fever at
the time of sampling.
Three samples (serum, oral ﬂuid, and nasopharyngeal secre-
tion) were collected simultaneously from each participant.
2.2. Sample treatment
Eachbloodsamplewascollected intoasterile tube, centrifugedat
2000 rpm (approximately 700 g) for 10min and stored at20 8C.
Oral ﬂuid samples were collected using the Oracol collection
device following the manufacturer’s instructions. Afterwards
(within 7 days), 1 ml of transport medium was added to each
collection device. The medium was phosphate-buffered saline
(PBS) pH 7.2 with 10% fetal calf serum, 0.2% Tween20, 0.5%gentamicin, and 0.2% fungizone (treatment for oral candidiasis).14
The addition of this transport medium has several purposes, ﬁrstly
it minimizes the effects of degradation of the oral ﬂuid and
secondly it facilitates pipetting. After adding thismedium, the vials
were centrifuged at 2000 rpm (approximately 700  g) for 5 min
and the oral ﬂuid was removed and stored at 20 8C.
The collection of nasopharyngeal secretions was performed
using a throat swab preserved in a transport medium containing
PBS (pH 7.2) with gentamicin and amphotericin.
Each set of three samples was collected within 3 days after the
onset of the exanthematous rash. All samples were centrifuged and
stored at 20 8C on the day of sampling at the National Measles
Laboratory in Kinshasa. The sets of three samples were shipped on
dry ice, by courier, from Kinshasa to the National Laboratory for
Measles and Rubella (NLMR) at the IPH in Brussels, Belgium. All oral
ﬂuid samples were visually checked for blood contamination.
Contaminated samples were rejected to avoid false-positive results.
To verify the quality of the oral ﬂuid samples, a total IgG
quantiﬁcation test was performed. To be acceptable for use in the
assays, the sample needed to contain at least a level of 0.625mg/ml
IgG (i.e., detection limit of the IgG quantiﬁcation assay). This test
was ﬁrst described for anti-HIV in urine15 and has been modiﬁed
for oral ﬂuid and eluates of dried blood by the Virus Reference
Laboratory, Health Protection Agency, London (2000). The assay
was performed at the NLMR according to the protocol of the Virus
Reference Laboratory.
2.3. Serological assays—detection of anti-measles IgM in serum and
oral ﬂuid
The detection of anti-measles IgM was performed using
Enzygnost Anti-Measles Virus IgM ELISA (Siemens, Germany) for
serum and a Measles IgM Capture EIA (MicroImmune, UK) for oral
ﬂuid on an automatic bench-top microplate analyzer (Etimax
3000, DiaSorin, Italy).
Serum and oral ﬂuid samples were independently and blindly
analyzed according to the manufacturer protocols.
2.4. Molecular assays—detection of measles virus RNA in
nasopharyngeal secretions and oral ﬂuid
The extraction of RNA from samples was performed using the
QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the
manufacturer’s protocol.
An in-house nested RT-PCR was developed, optimized, and
validated. Three dilutions of the reference Schwarz vaccine strain
containing 20 000 international units (IU)/ml and negative controls
were designed for this purpose.
For the PCR on nasopharyngeal secretions, 1/1000 (20 IU/ml), 1/
5000 (4 IU/ml), and 1/8000 (2.5 IU/ml) dilutions of the Schwarz
vaccine strain into MRC5 cells were used as positive controls and
MRC5 cells were used as negative control.
A 1/100 (200 IU/ml), 1/1000 (20 IU/ml), and 1/5000 (4 IU/ml)
dilution series of the Schwarz vaccine strain in negative oral ﬂuid
was used as positive controls in a PCR performed on saliva samples.
For this latter PCR, negative oral ﬂuid was used as the negative
control.
RNA was reverse-transcribed and cDNA ampliﬁed using a one-
step RT-PCR kit, followed by a nested PCR with speciﬁc primers for
themeasles virus N-gene region: KVW-1 (external forward), KVW-
2R (external reverse), MV-1172 (internal forward), and KVW-4R
(internal reverse).16,17 A human b-actin fragment was ampliﬁed
with primers developed in-house as internal control for the
integrity of RNA and the efﬁciency of the reactions for both PCRs.
The speciﬁc primers for the targeted region in the RT-PCR were
b-actin 5 (50 AACACCCCAGCCATGTAC 30) and b-actin 6
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8 (50 GTTGCTATCCAGGCTGTGC 30 and 50 GCCAGCCAGGTCCAGACG
30, respectively) were used.18,19
For the RT-PCR performed by the PTC-200 DNA Engine1
Thermal Cycler (Bio-Rad, Belgium), 10 ml RNA was added to 40 ml
of a Promega Access-Quick master mix containing Quick master
mix buffer (2  ), 12.5 pmol/ml MV primers (KVW-1 and KVW-2R),
50 pmol/ml b-actin primers (5 + 6), 5 U/ml Avian Myeloblastosis
Virus (AMV) Reverse Transcriptase, and nuclease-free H2O. The
steps of the RT-PCR reaction (3 h) were: the mix was kept at 48 8C
for 45 min, followed by 94 8C for 2 min, followed by 40 cycles with
each a denaturation at 94 8C for 30 s, annealing at 55 8C for 30 s, and
an elongation step at 68 8C for 30 s. In a ﬁnal step, the mix was kept at
68 8C for 7 min.
The second ampliﬁcation step (i.e., in-house developed nested
PCR) was performedwith a total mix of 50 ml containing 10Mg2+
buffer (Roche), 10 mM dNTPs (Roche), 12.5 pmol/ml MV-1172 and
KVW-4R primers, 50 pmol/ml b-actin primers (7 + 8), 5 U/ml Taq
DNA polymerase (Roche), nuclease-free H2O, and 2.5 ml cDNA
(from RT-PCR). The nested PCR reaction ( 2 h) involves keeping the
mix at 94 8C for 6 min, followed by 40 cycleswith each a denaturation
step at 94 8C for 30 s, an annealing at 55 8C for 30 s, and an elongation
step at 72 8C for 30 s. Finally, the mix was kept at 72 8C for 10 min.
After ampliﬁcation, the PCR products were visualized on a Bio-
Rad UV-transilluminator.
Nasopharyngeal secretions and oral ﬂuid samples were inde-
pendently and blindly analyzed according to in-house procedures.
A PCR result was considered valid when the positive control for
PCR on nasopharyngeal secretions at 1/8000 dilution (2.5 IU/ml)
and oral ﬂuid at 1/5000 dilution (4 IU/ml) gave a positive outcome.
This ensures that the in-house developed PCR for nasopharyngeal
secretions and oral ﬂuid has a sensitivity of >99%.
Samples with an amplicon at 254 bp (presence of measles virus)
and144 bp(b-actin)ongelelectrophoresiswereconsideredpositive
for MV. If no signal was detected at 254 bp, in the presence of the
b-actinsignal (internalcontrol), thesamplewasconsiderednegative
forMV. In the absence of theb-actin signal, the PCRwas considered
invalid and the test was repeated from the extraction step.
2.5. Statistical analysis
The kappa coefﬁcient was calculated to determine the level of
agreement between assays (serum vs. oral ﬂuid, and nasopharyn-
geal secretions vs. oral ﬂuid).20
3. Results
3.1. Serological assays
All 117 oral ﬂuid and serum samples were tested for anti-
measles IgM using the described serological assays. In this study,
73 out of 117 serum sampleswere IgM-positive in accordancewith
the clinical measles diagnosis and 44 were IgM-negative (Tables 1
and 2). All positive samples and 28 negative samples wereTable 1
Results of ELISA assays for the detection of anti-measles IgM in oral ﬂuid and serum
Oral ﬂuid Serum
Positive Negative Total
Positive 67 0 67
Negative 6 44 50
Total 73 44 117
ELISA on oral ﬂuid (MicroImmune) versus serum (Siemens =gold standard);
sensitivity: 67/73100=92% (95% CI 84.7–97.7%); speciﬁcity: 44/44100=100%
(95% CI 92.9–100%).collected in a ghetto in Kinshasa in the Democratic Republic of
Congo. Sixteen negative samples came from volunteers working at
the IPH, Brussels, Belgium.
The oral ﬂuid of 67 out of the 73 anti-measles seropositive
subjects tested positively. The oral ﬂuid of all 44 anti-measles
seronegative subjects tested negatively. These results show that
the measles IgM capture EIA on oral ﬂuid has a sensitivity of 92%
(95% CI 84.7–97.7) and speciﬁcity of 100% (95% CI 92.9–100). The
strength of agreement between the assays was very good
(k = 0.90). Two technicians on two different Etimax 3000
machines analyzed all oral ﬂuid and serum samples blindly at
different times.
The Measles IgM Capture EIA was evaluated and compared to
Enzygnost Anti-Measles Virus IgM ELISA. In this study, no false-
positive or false-negative results were obtained with the Measles
IgM Capture EIA on serum, so the speciﬁcity was even higher than
that reported on the manufacturer’s datasheet (sensitivity 100%,
speciﬁcity 96.1%). However, the Enzygnost Anti-Measles Virus IgM
ELISA, which had a sensitivity of >99.9% and a speciﬁcity of
>99.9%, remained the gold standard in this study.
The results for the 117 samples obtained by the different
serological and molecular assays are shown in Table 2.
3.2. Molecular assays
The optimized and validated PCR assays on oral ﬂuid and
nasopharyngeal secretions were performed for their validation on
clinical samples. Two technicians evaluated the in-house devel-
oped nested RT-PCR at different times and on different thermo-
cyclers. Logarithmic and semi-logarithmic dilutions (from 101 up
to 106.5) of a standard reference strain (Schwarz vaccine strain
containing 20 000 IU/ml) were performed for both sample types.
Each dilution was analyzed 24 times. The results were subjected to
a probit analysis (by Xlstat 4.0).
In each run of the in-house developed nested RT-PCR on
nasopharyngeal secretions, three positive controls (1/1000, 1/
5000, and 1/8000 dilution of reference Schwarz strain in negative
control containing MRC5 cells) were included (Figure 1). After
validation, the 99% end-point was calculated and it corresponded
to the 1/8000 dilution containing 2 IU/ml. This dilutionwas chosen
as a positive validation control for each run using nasopharyngeal
secretions.
The in-house nested RT-PCR on oral ﬂuid also included three
positive controls (1/100, 1/1000, and 1/5000 dilution of the
reference Schwarz strain in negative saliva) in each run (Figure 2).
The 1/5000 dilution (i.e., 4 IU/ml) corresponded to the 99% end-
point and was chosen as a positive validation control for each run
using oral ﬂuid.
The optimized in-house nested RT-PCR on nasopharyngeal
secretions and oral ﬂuid was also tested on positive MV RNA
samples of different genotypes, such as genotype A, B3, D4, D5, D6
and D9.
For the validation on clinical samples, all 117 oral ﬂuid samples
and nasopharyngeal secretions were tested for MV RNA using the
above described PCRs. Our results show that 73 out of 117
nasopharyngeal secretions were MV RNA-positive (Table 2),
conﬁrming the clinical measles diagnosis. All 73 MV RNA-positive
nasopharyngeal secretions were also positive for oral ﬂuid.
Similarly, the 44 MV RNA-negative nasopharyngeal secretions
were also negative for oral ﬂuid. Using nasopharyngeal secretions
as the gold standard the results show that the nested RT-PCR on
oral ﬂuid has a sensitivity of 100% (95% CI 95.1–100) and speciﬁcity
of 100% (95% CI 92.9–100). The positive and negative predictive
values were 100% (95% CI 95.1–100) and 100% (95% CI 92.9–100),
respectively. The strength of agreement between the assays was
very good (k = 1).
Table 2
ELISA and PCR results obtained for the detection of anti-measles IgM (oral ﬂuid and serum) and measles virus RNA (oral ﬂuid and nasopharyngeal secretions), respectively
Sample
number
ELISA Micro
sera
OD Micro
serb
CO Micro ser OD/CO
Micro serc
ELISA Micro
sald
OD Micro
sale
CO Micro sal OD/CO
Micro salf
PCR
nasog
PCR
salh
Mea/01 POS 3.248 0.372 8.731 POS 1.949 0.243 8.021 POS POS
Mea/02 POS 3.254 0.372 8.747 POS 3.635 0.243 14.959 POS POS
Mea/03 POS 0.869 0.372 2.336 NEG 0.184 0.243 0.757 POS POS
Mea/04 POS 1.658 0.372 4.457 POS 3.699 0.243 15.222 POS POS
Mea/05 POS 4.435 0.372 11.922 POS 1.231 0.243 5.066 POS POS
Mea/06 POS 2.036 0.372 5.473 wPOS 0.285 0.243 1.173 POS POS
Mea/07 POS 1.657 0.372 4.454 POS 0.971 0.243 3.996 POS POS
Mea/08 POS 1.294 0.372 3.478 NEG 0.143 0.243 0.588 POS POS
Mea/09 POS 1.674 0.372 4.500 POS 3.299 0.243 13.576 POS POS
Mea/10 POS 4.365 0.372 11.734 POS 1.948 0.243 8.016 POS POS
Mea/11 POS 3.91 0.372 10.511 POS 4.442 0.243 18.280 POS POS
Mea/12 POS 1.671 0.372 4.492 POS 0.639 0.243 2.630 POS POS
Mea/13 POS 2.797 0.372 7.519 wPOS 0.460 0.243 1.893 POS POS
Mea/14 POS 1.445 0.372 3.884 NEG 0.157 0.243 0.646 POS POS
Mea/15 POS 0.771 0.372 2.073 POS 1.844 0.243 7.588 POS POS
Mea/16 POS 4.189 0.372 11.261 POS 2.193 0.243 9.025 POS POS
Mea/17 POS 3.482 0.372 9.360 POS 2.284 0.243 9.399 POS POS
Mea/18 POS 2.212 0.372 5.946 NEG 0.154 0.243 0.634 POS POS
Mea/19 POS 1.45 0.372 3.898 wPOS 0.244 0.243 1.004 POS POS
Mea/20 POS 2.819 0.372 7.578 wPOS 0.413 0.243 1.700 POS POS
Mea/21 POS 1.556 0.372 4.183 wPOS 0.485 0.243 1.996 POS POS
Mea/22 POS 3.568 0.372 9.591 POS 2.934 0.243 12.074 POS POS
Mea/23 POS 3.398 0.372 9.134 POS 3.571 0.243 14.695 POS POS
Mea/24 POS 3.517 0.372 9.454 POS 0.558 0.243 2.296 POS POS
Mea/25 POS 1.205 0.372 3.239 wPOS 0.327 0.243 1.346 POS POS
Mea/26 POS 0.777 0.372 2.089 NEG 0.137 0.243 0.564 POS POS
Mea/27 POS 3.565 0.372 9.583 POS 3.075 0.243 12.654 POS POS
Mea/28 POS 3.242 0.389 8.334 POS 3.382 0.224 15.098 POS POS
Mea/29 POS 1.487 0.389 3.823 wPOS 0.341 0.224 1.522 POS POS
Mea/30 POS 4.064 0.389 10.447 POS 2.803 0.224 12.513 POS POS
Mea/31 POS 3.878 0.389 9.969 POS 4.410 0.224 19.688 POS POS
Mea/32 POS 1.349 0.389 3.468 POS 0.531 0.224 2.371 POS POS
Mea/33 POS 4.586 0.389 11.789 POS 3.856 0.224 17.214 POS POS
Mea/34 POS 2.87 0.389 7.378 POS 0.923 0.224 4.121 POS POS
Mea/35 POS 4.086 0.389 10.504 POS 2.883 0.224 12.871 POS POS
Mea/36 POS 3.011 0.389 7.740 POS 4.144 0.224 18.500 POS POS
Mea/37 POS 5.133 0.389 13.195 POS 1.185 0.224 5.290 POS POS
Mea/38 POS 4.858 0.389 12.488 POS 5.200 0.224 23.214 POS POS
Mea/39 POS 3.715 0.389 9.550 POS 2.730 0.224 12.188 POS POS
Mea/40 POS 0.825 0.389 2.121 NEG 0.197 0.224 0.879 POS POS
Mea/41 POS 2.826 0.389 7.265 POS 0.900 0.224 4.018 POS POS
Mea/42 POS 3.92 0.389 10.077 POS 1.426 0.224 6.366 POS POS
Mea/43 POS 1.625 0.389 4.177 wPOS 0.270 0.224 1.205 POS POS
Mea/44 POS 1.276 0.389 3.280 wPOS 0.326 0.224 1.455 POS POS
Mea/45 POS 2.768 0.389 7.116 wPOS 0.340 0.224 1.518 POS POS
Mea/46 POS 2.427 0.389 6.239 POS 0.514 0.224 2.295 POS POS
Mea/47 POS 3.539 0.389 9.098 POS 4.653 0.224 20.772 POS POS
Mea/48 POS 2.883 0.389 7.411 POS 0.462 0.224 2.063 POS POS
Mea/49 POS 4.656 0.389 11.969 POS 4.938 0.224 22.045 POS POS
Mea/50 POS 2.157 0.389 5.545 POS 3.226 0.224 14.402 POS POS
Mea/51 POS 3.331 0.389 8.563 POS 1.530 0.224 6.830 POS POS
Mea/52 POS 5.088 0.389 13.080 POS 5.091 0.224 22.728 POS POS
Mea/53 POS 4.118 0.389 10.586 POS 3.555 0.224 15.871 POS POS
Mea/54 POS 4.07 0.389 10.463 POS 4.618 0.224 20.616 POS POS
Mea/55 POS 4.506 0.389 11.584 POS 3.347 0.224 14.942 POS POS
Mea/56 POS 2.928 0.389 7.527 POS 3.178 0.224 14.188 POS POS
Mea/57 POS 2.086 0.389 5.362 POS 0.879 0.224 3.924 POS POS
Mea/58 POS 1.912 0.389 4.915 POS 1.002 0.224 4.473 POS POS
Mea/59 POS 2.002 0.389 5.147 POS 0.639 0.224 2.853 POS POS
Mea/60 POS 4.314 0.389 11.090 POS 3.382 0.224 15.098 POS POS
Mea/61 POS 4.096 0.389 10.530 POS 4.618 0.224 20.616 POS POS
Mea/62 POS 5.04 0.389 12.956 POS 5.062 0.224 22.598 POS POS
Mea/63 POS 3.306 0.389 8.499 POS 0.768 0.224 3.429 POS POS
Mea/64 POS 3.91 0.389 10.051 POS 4.115 0.224 18.371 POS POS
Mea/65 POS 2.336 0.389 6.005 POS 0.643 0.224 2.871 POS POS
Mea/66 POS 3.062 0.389 7.871 POS 0.812 0.224 3.625 POS POS
Mea/67 POS 1.611 0.389 4.141 POS 0.660 0.224 2.946 POS POS
Mea/68 POS 3.59 0.389 9.229 POS 3.731 0.224 16.656 POS POS
Mea/69 POS 4.582 0.389 11.779 POS 4.797 0.224 21.415 POS POS
Mea/70 POS 4.253 0.389 10.933 POS 4.710 0.224 21.027 POS POS
Mea/71 POS 1.48 0.389 3.805 POS 2.101 0.224 9.379 POS POS
Mea/72 POS 1.862 0.389 4.787 POS 2.189 0.224 9.772 POS POS
Mea/73 POS 4.147 0.389 10.661 POS 4.736 0.224 21.143 POS POS
Mea/74 NEG 0.071 0.372 0.191 NEG 0.055 0.243 0.226 NEG NEG
Mea/75 NEG 0.184 0.372 0.495 NEG 0.037 0.243 0.152 NEG NEG
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Table 2 (Continued )
Sample
number
ELISA Micro
sera
OD Micro
serb
CO Micro ser OD/CO
Micro serc
ELISA Micro
sald
OD Micro
sale
CO Micro sal OD/CO
Micro salf
PCR
nasog
PCR
salh
Mea/76 NEG 0.062 0.372 0.167 NEG 0.031 0.243 0.128 NEG NEG
Mea/77 NEG 0.094 0.372 0.253 NEG 0.035 0.243 0.144 NEG NEG
Mea/78 NEG 0.062 0.372 0.167 NEG 0.038 0.243 0.156 NEG NEG
Mea/79 POS 0.643 0.372 1.728 NEG 0.051 0.243 0.210 NEG NEG
Mea/80 NEG 0.115 0.372 0.309 NEG 0.057 0.243 0.235 NEG NEG
Mea/81 NEG 0.063 0.372 0.169 NEG 0.055 0.243 0.226 NEG NEG
Mea/82 NEG 0.153 0.372 0.411 NEG 0.067 0.243 0.276 NEG NEG
Mea/83 NEG 0.052 0.372 0.140 NEG 0.049 0.243 0.202 NEG NEG
Mea/84 NEG 0.153 0.372 0.411 NEG 0.072 0.243 0.296 NEG NEG
Mea/85 NEG 0.131 0.372 0.352 NEG 0.036 0.243 0.148 NEG NEG
Mea/86 NEG 0.18 0.372 0.484 NEG 0.052 0.243 0.214 NEG NEG
Mea/87 NEG 0.177 0.372 0.476 NEG 0.058 0.243 0.239 NEG NEG
Mea/88 NEG 0.173 0.372 0.465 NEG 0.032 0.243 0.132 NEG NEG
Mea/89 NEG 0.063 0.372 0.169 NEG 0.045 0.243 0.185 NEG NEG
Mea/90 NEG 0.06 0.372 0.161 NEG 0.046 0.243 0.189 NEG NEG
Mea/91 NEG 0.227 0.372 0.610 NEG 0.060 0.243 0.247 NEG NEG
Mea/92 NEG 0.075 0.372 0.202 NEG 0.042 0.243 0.173 NEG NEG
Mea/93 NEG 0.096 0.372 0.258 NEG 0.065 0.243 0.267 NEG NEG
Mea/94 NEG 0.118 0.372 0.317 NEG 0.065 0.243 0.267 NEG NEG
Mea/95 NEG 0.15 0.372 0.403 NEG 0.159 0.243 0.654 NEG NEG
Mea/96 NEG 0.075 0.372 0.202 NEG 0.066 0.243 0.272 NEG NEG
Mea/97 NEG 0.179 0.372 0.481 NEG 0.067 0.243 0.276 NEG NEG
Mea/98 NEG 0.064 0.389 0.165 NEG 0.027 0.224 0.121 NEG NEG
Mea/99 NEG 0.171 0.389 0.440 NEG 0.040 0.224 0.179 NEG NEG
Mea/100 NEG 0.083 0.389 0.213 NEG 0.041 0.224 0.183 NEG NEG
Mea/101 NEG 0.06 0.389 0.154 NEG 0.038 0.224 0.170 NEG NEG
Mea/102 NEG 0.184 0.389 0.473 NEG 0.150 0.224 0.670 NEG NEG
Mea/103 NEG 0.324 0.389 0.833 NEG 0.044 0.224 0.196 NEG NEG
Mea/104 NEG 0.085 0.389 0.219 NEG 0.042 0.224 0.188 NEG NEG
Mea/105 NEG 0.077 0.389 0.198 NEG 0.046 0.224 0.205 NEG NEG
Mea/106 NEG 0.046 0.389 0.118 NEG 0.060 0.224 0.268 NEG NEG
Mea/107 NEG 0.203 0.389 0.522 NEG 0.058 0.224 0.259 NEG NEG
Mea/108 NEG 0.101 0.389 0.260 NEG 0.042 0.224 0.188 NEG NEG
Mea/109 NEG 0.053 0.389 0.136 NEG 0.041 0.224 0.183 NEG NEG
Mea/110 NEG 0.097 0.389 0.249 NEG 0.062 0.224 0.277 NEG NEG
Mea/111 NEG 0.125 0.389 0.321 NEG 0.063 0.224 0.281 NEG NEG
Mea/112 NEG 0.075 0.389 0.193 NEG 0.057 0.224 0.254 NEG NEG
Mea/113 NEG 0.092 0.389 0.237 NEG 0.049 0.224 0.219 NEG NEG
Mea/114 NEG 0.104 0.389 0.267 NEG 0.070 0.224 0.313 NEG NEG
Mea/115 NEG 0.203 0.389 0.522 NEG 0.066 0.224 0.295 NEG NEG
Mea/116 NEG 0.075 0.389 0.193 NEG 0.036 0.224 0.161 NEG NEG
Mea/117 NEG 0.066 0.389 0.170 NEG 0.057 0.224 0.254 NEG NEG
OD, optical density; CO, cut-off; PCR, polymerase chain reaction; POS, positive result; wPOS, weak positive result; NEG, negative result.
a ELISA Micro ser: qualitative result for each serum sample obtained by the Measles IgM Capture EIA (MicroImmune, UK).
b OD Micro ser: OD of each serum sample of the Measles IgM Capture EIA (MicroImmune, UK).
c OD/CO Micro ser: ratio of the OD/CO of the Measles IgM Capture EIA (MicroImmune, UK) for each serum sample.
d ELISA Micro sal: qualitative result for each oral ﬂuid sample obtained by the Measles IgM Capture EIA (MicroImmune, UK).
e OD Micro sal: optical density of each oral ﬂuid sample of the Measles IgM Capture EIA (MicroImmune, UK).
f OD/CO Micro sal: ratio of the OD/CO the Measles IgM Capture EIA (MicroImmune, UK) for each oral ﬂuid sample.
g PCR naso: qualitative results of the in-house nested reverse transcriptase (RT)-PCR on nasopharyngeal secretions.
h PCR sal: qualitative results of the in-house nested RT-PCR on oral ﬂuid.
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make sure that no other exanthematous virus could be detected by
these PCRs. Different dilutions of the rubella virus (80–800 IU/ml),
parvovirus B19 (104–105 IU/ml), and mumps virus (800–8000 IU/[(Figure_1)TD$FIG]
Figure 1. Nested RT-PCR on nasopharyngeal secretions showing positive and
negative controls and measles positive and negative results. Lane 1: positive
nasopharyngeal control (PC naso) (1/1000 dilution = 20 IU/ml); lane 2: PC naso (1/
5000 dilution = 4 IU/ml); lane 3: PC naso (1/8000 dilution = 2.5 IU/ml); lane 4:
negative nasopharyngeal control (NC = MRC5 cells); lanes 5, 6, 7, 8 and 10:
nasopharyngeal sample positive for measles virus RNA; lane 9: nasopharyngeal
sample negative for measles virus RNA.ml) were tested. The measles PCRs did not give a positive result for
any of these viruses.
The accurate detection of a panel consisting of 12 dilutions
positive forMV RNA (i.e., 2000 IU/ml), alternatingwith 12 negative
oral ﬂuid samples, proved the absence of contamination during the
test, since the negative samples remained negative for MV RNA
after PCR.
[(Figure_2)TD$FIG]Figure 2. Nested RT-PCR on oral ﬂuid showing positive and negative controls and
measles positive and negative results. Lane 1: positive oral ﬂuid control (PC OF) (1/
100 dilution = 200 IU/ml); lane 2: PC OF (1/1000 dilution = 20 IU/ml); lane 3: PC OF
(1/5000 dilution = 4 IU/ml); lane 4: oral ﬂuid sample positive formeasles virus RNA;
lane 5: negative oral ﬂuid control; lanes 6, 7, 8 and 9: oral ﬂuid sample positive for
measles virus RNA; lane 10: oral ﬂuid sample negative for measles virus RNA.
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Our results show that oral ﬂuid assays are suitable for routine
laboratory conﬁrmation in the diagnosis of measles cases. The oral
ﬂuid assay should make it easier for patients, GPs, and
pediatricians to participate in the Belgian measles surveillance
system and epidemiological studies (e.g., seroprevalence surveys).
The collection of oral ﬂuid, unlike blood collection, is non-
invasive, less painful, safe, and less expensive (i.e., no trained
personnel required). Furthermore, only one sample (i.e., oral ﬂuid)
needs to be collected for serological, as well as molecular analysis.
This study shows that serological and molecular assays
performed on oral ﬂuid samples have a very high sensitivity and
speciﬁcity compared with the gold standard tests on serum and
nasopharyngeal secretion samples. The level of agreement
between the commercially available EIA and ELISA for the
detection of anti-measles IgM in oral ﬂuid and serum was very
good (k = 0.90). The in-house nested RT-PCR assays for the
detection of MV RNA in oral ﬂuid and nasopharyngeal secretions
also resulted in a very good level of agreement (k = 1).
The excellent concordance of the PCR on oral ﬂuid and
nasopharyngeal secretions shows that nasopharyngeal samples
can be replaced by oral ﬂuid for the detection of MV RNA. In our
study, samples were taken at an early stage of the disease, after the
onset of the rash, when the viremia was still very high. This was
probably the major reason for the high level of concordance
between the two PCRs.
Previous studies have demonstrated that nasopharyngeal
secretions can be replaced by oral ﬂuid for measles virus detection,
without loss of reliability.21,22
Six oral ﬂuid samples out of 73 were IgM-negative, although
the corresponding sera were positive. Since all samples were
subjected to an IgG quantiﬁcation assay, which showed that
they all contained sufﬁcient total IgG, an inadequate sample
collection procedure could be excluded. These negative results
could be explained by the timing of sample collection, since
samples were collected at different times within 3 days after the
onset of the rash. This is in line with the previously described
study of Perry et al. who used a monoclonal IgM capture EIA23
and proved that the sensitivity of a measles IgM assay depends
on the timing of sample collection. An alternative explanation is
that these negative results came from cases with a lower IgM
concentration, which was detectable in serum (weakly positive)
using the Enzygnost Anti-Measles Virus IgM ELISA (Table 2),
since IgM is at a higher concentration in serum than in oral
ﬂuid.10
The high efﬁciency of the Oracol collection device (targeting
GCF) has also been conﬁrmed in oral ﬂuid samples used for
detecting anti-measles IgM and MV.12 The use of this device
reduces the presence of interfering factors, such as water, protein
inorganic salts, mucin, and enzymes.6 Although the salivary gland
secretion contains most of the IgA, the GCF contains the highest
concentrations of IgG and IgM.12
The Oracol device speciﬁcally collects oral ﬂuid from areas of
the mouth rich in crevicular ﬂuid. There is good correlation
between the performance of these oral ﬂuid samples and sera in
antibody assays of immunoglobulin concentrations.12 In addition,
it has been shown that participants favor the Oracol collection
device over other sample collection methods.12
Previous studies have demonstrated that oral ﬂuid can be used
as a good alternative to serum for the detection of different viruses
such as hepatitis A, B and C viruses, human immunodeﬁciency
virus, measles and rubella.7,8,11,21–41
No other study groups have used identical assays and
procedures, therefore it is not possible to extrapolate the
sensitivities achieved in the present study on oral ﬂuid (92% forthe serological assay and 100% for the molecular assay) with those
obtained by other study groups.21–24,29,31,34,38,39
Helfand et al. used their own antibody capture EIA for the
detection of measles IgM in oral ﬂuid using the OraSure collection
device.29 They compared the oral ﬂuid assay with the traditional
serum assay and obtained a sensitivity of 91% and speciﬁcity of
95%.
Perry et al. developed an in-house M-antibody capture
radioimmunoassay (MACRIA) for oral ﬂuid. They collected oral
ﬂuid by dribbling into a sterile plastic container.34 In their study, a
distinction was made in the sensitivity obtained at the different
time points of sample collection, i.e. ﬁrst 7 days following the rash,
or within 1–5 weeks after the appearance of the rash. For these
time points, they measured a sensitivity of 92% and 100%,
respectively.
Although both research groups used other serological assays,
we can assume that the obtained sensitivity of 92% with the EIA
from MicroImmune is an excellent result. Van Binnendijk et al.
used another molecular assay–real-time PCR, which is generally
known as amore sensitive assay in comparisonwith the traditional
nested RT-PCR.22 Although, they mentioned a detection limit of
0.01–0.001 IU/ml, it was not clear in their paper towhich end-point
it corresponded.
In 2007, Thomas et al. also described the evaluation of a real-
time PCR for the rapid detection of MV RNA in oral ﬂuid.38 The
major difference between the real-time PCR of Thomas et al. and
Van Binnendijk et al. was the choice of the targeted gene: H-gene
and N-gene of the measles genome, respectively. Thomas et al.
routinely performed the real-time PCR (H-gene) and nested RT-
PCR (N-gene) in parallel for the purposes of genotyping. However,
they found the real-time PCR to be more sensitive and rapid.
In our nested RT- PCR, 4 IU/ml corresponds to the 99% end-point
for the detection of MV in oral ﬂuid. In every run, a positive control
containing 4 IU/ml is introduced and should be positive. In some
cases we were able to detect 0.02 IU/ml, however no 95% or 99%
end-point could be guaranteed.
Our results show that our in-house developed nested RT-PCR on
oral ﬂuid has a very good sensitivity (100%). However, it should be
mentioned that the MV RNA positivity depends on the time-point
of sampling, which, of course, has an inﬂuence on the calculation of
the sensitivity of the assay. MV RNA can be detected verywell until
7 days after the onset of the rash.3,22 Afterwards the measles
viremia declines rapidly, but remains detectable until 2 weeks
after the appearance of the rash.
Different European countries have already implemented oral
ﬂuid assays in their measles surveillance systems. Oral ﬂuid
sampling is recommended by the WHO as a suitable surveillance
tool for measles. Measles IgM and MV RNA have been proven to be
detectable very early after the onset of symptoms.3,4 A compara-
tive study has demonstrated that results obtained on oral ﬂuid and
dried blood spots are comparable to those obtained on serum. A
very good result was achieved for the detection of measles IgM and
MV RNA in oral ﬂuid, which was not the case for the dried blood
spots.3
In the UK, oral ﬂuid assays for the detection of measles have
been carried out since the beginning of the 1990s.5,23 Between
1995 and 2001 in England and Wales, the program to eliminate
measles resulted in a surveillance campaign in some schools. This
surveillance relied upon oral ﬂuid sampling, and interesting and
reliable results were produced.40 The Department of Health in
England even recommended that all suspected cases of measles
should be tested for the presence of salivary measles IgM. In
Ireland, they used oral ﬂuid samples to evaluate the molecular
epidemiology of circulating measles virus from 2002 to 2007.41 In
Belgium, oral ﬂuid sampling has been shown to be a useful tool in
the surveillance and control of the recent measles outbreak in
V. Hutse et al. / International Journal of Infectious Diseases 14 (2010) e991–e997 e997Antwerp.42 These studies prove that oral ﬂuid is already a standard
approach for measles detection in different European countries.
The implementation of oral ﬂuid sample collection has
signiﬁcant advantages over the sampling and analysis of serum
and/or nasopharyngeal secretions in measles virus surveillance.
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